Conmed (CNMD) Tops Q3 EPS by 3c; offers guidance

Conmed (NYSE: CNMD) reported Q3 EPS of $1.08, $0.03 better than the analyst estimate of $1.05. Revenue for the quarter came in at $337.9 million versus the consensus estimate of $334.71 million.

GUIDANCE:

Conmed sees FY2025 EPS of $4.48-$4.53, versus the consensus of $4.47. Conmed sees FY2025 revenue of $1.365-1.372 billion, versus the consensus of $1.367 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Lockheed Martin wins $871 million F-35 contract modification
• SmartKem (SMTK) files for 15.13M share offering by selling stockholders